Bolt Biotherapeutics Inc

BOLT | $1.12 -1.75% -1.79% 55K

(0.0% 1d) (-4.3% 1m) (-27.5% 1y) (0.0% 2d) (0.0% 3d) (-1.8% 7d) (-45.88% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 42,703,069
https://boltbio.com
Sec Filling | Patents | 65 employees

(US) Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.

ceiling treatment antibody t-cell

add to watch list Paper trade email alert is off

Press-releases

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Published: 2024-03-21 (Crawled : 20:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| -4.31% | O: 0.0% H: 3.45% C: 3.45%
business update financial results

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| -9.02% | O: -0.82% H: 1.55% C: -0.83%
conference

Pacira Appoints Frank D. Lee as Chief Executive Officer
Published: 2023-12-21 (Crawled : 12:30) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 9.9% | O: 0.0% H: 5.94% C: -1.47%
PCRX | $26.24 0.54% 0.53% 450K

Health Technology

| -18.5% | O: 0.09% H: 3.5% C: 2.26%

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
Published: 2023-12-05 (Crawled : 12:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 21.5% | O: 0.7% H: 3.6% C: 1.1%
bdc-1001 enhertu breast cancer study

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 13.27% | O: 0.0% H: 2.04% C: -1.02%
business update financial results

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 11.0% | O: 5.0% H: 0.0% C: -5.71%
conference

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
Published: 2023-10-23 (Crawled : 14:30) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 7.77% | O: 0.96% H: 0.01% C: -8.67%
bdc-1001 nivolumab congress tumors trial

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
Published: 2023-10-18 (Crawled : 11:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 11.0% | O: 1.0% H: 3.96% C: 1.98%
immunotherapy meeting

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 8.82% | O: 1.96% H: 0.0% C: -3.85%
bdc-3042 study

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K

| 15.63% | O: 2.04% H: 8.21% C: 4.12%
bdc-1001 congress tumors trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-026998	4	2024-03-06	2024-03-04	Buy	A	235000	235000
0000950170-24-026997	4	2024-03-06	2024-03-04	Buy	A	654000	235000
0000950170-24-026996	4	2024-03-06	2024-03-04	Buy	A	235000	235000